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 Introduction 
 Vascular dementia is a broad term encompassing het-
erogeneous clinical and pathological syndromes  [1] . Rec-
ognizing the need for well-defined and homogeneous 
subtypes of vascular dementia, new research criteria have 
been proposed for subcortical vascular dementia (SVaD) 
 [2] , which is presumed to be the most common type of 
vascular dementia. These criteria emphasize small vessel 
disease as the chief vascular etiology, lacunar infarcts and 
ischemic white matter lesions as the primary type of 
brain lesions, subcortical location as the primary location 
of the lesions, and the subcortical clinical syndrome as 
the primary clinical manifestation  [2] . The new criteria 
are expected to lead to a more predictable clinical presen-
tation, natural history, outcome and treatment respons-
es  [2] .
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 Abstract 
 Background and Purpose: New research criteria for subcor-
tical vascular dementia (SVaD) have been suggested to de-
fine a more homogeneous subgroup of vascular dementia. 
Hippocampal (Hc) atrophy is a hallmark of Alzheimer’s dis-
ease (AD), but it also occurs in other dementia disorders in-
cluding vascular dementias. So far, it is unknown to which 
extent Hc atrophy is present in SVaD.  Methods: From a larg-
er consecutive referral population in a memory clinic, 11 pa-
tients fulfilling the research criteria for SVaD were carefully 
matched with comparison groups of healthy controls and 
patients with AD. To estimate the extent of Hc atrophy in 
SVaD, both Hc volumetry and visual rating of medial tempo-
ral lobe atrophy (MTA) were applied.  Results: In SVaD, sig-
nificant Hc atrophy occurred. The extent was intermediate 
between controls and patients with AD both on Hc volum-
etry and visual MTA ratings. At the same level of global cog-
nition, Hc volumes were reduced by 11.6% in SVaD and 16.6% 
in AD, relative to controls.  Conclusions: Patient groups with 
AD and SVaD as identified by current research criteria appear 
to overlap considerably with regard to the feature of Hc at-
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 Hippocampal (Hc) atrophy frequently occurs in Alz-
heimer’s disease (AD)  [3–6] , but also in other dementia 
disorders  [7–9] . A number of previous studies reported 
evidence of significant Hc atrophy in vascular dementia 
 [7, 9–14] , and one recent study stressed the relevance of 
Hc atrophy regarding treatment responses in a random-
ized trial  [15] . However, these findings have been based 
on heterogeneous definitions of vascular dementia and 
often included patients with cortical lesions. So far, it re-
mains unclear to which extent Hc atrophy is present in 
SVaD.
 In this study, we therefore investigated Hc atrophy on 
MRI in SvaD in comparison to AD and healthy control 
subjects. We used both Hc volumetry and visual ratings 
of medial temporal lobe atrophy (MTA)  [5] .
 Methods 
 Subjects and Pair-Matching Procedure 
 The subjects were recruited from all patients and controls seen 
at the Free University Medical Center (VUMC) Amsterdam be-
tween January 2000 and June 2003. The new SVaD criteria  [2] 
were operationalized in the following way: all patients had to have 
both (a) objective impairment of memory and executive functions 
(cognitive phenotype of SVaD) and (b) extending periventricular 
and deep white matter lesions on brain MRI (radiological pheno-
type of SVaD). Patients with cortical infarcts were excluded. Of 
all patients seen at the VUMC, 11 met these criteria for SVaD  [2] .
 In the same time period (January 2000 to December 2003), 77 
patients were diagnosed with AD according to the NINCDS re-
search criteria and published diagnostic procedures  [5] . Of those, 
11 patients were selected who optimally matched the SVaD pa-
tients in age, gender and severity of cognitive impairment. Re-
corded results from the Mini-Mental State Examination (MMSE) 
 [16] and the global score of the Clinical Dementia Rating (CDR) 
scale  [17] were used to match the disease groups for severity of 
cognitive impairment. 
 Thirty-one healthy control subjects were recruited through 
advertisements and among spouses and friends of demented pa-
tients. They did not report any cognitive complaints. Eleven con-
trols matching the vascular dementia patients in age and gender 
were chosen.
 Clinical and Neuropsychological Instruments 
 The MMSE  [16] and CDR scale  [17] belong to a set of standard 
batteries routinely used at the VUMC. The CDR was based on 
information from both patients and a collateral source, and was 
determined according to published rules  [17] .
 MRI Acquisition 
 MRI was conducted with a 1.0-tesla tomograph (Siemens 
Magnetom Impact Expert, Erlangen, Germany) using a magneti-
zation-prepared rapid gradient echo (MPRAGE) and a fluid-at-
tenuated inversion recovery (FLAIR) sequence with the following 
characteristics: (1) MPRAGE – coronal, TR = 15 ms, TE = 7 ms, 
TI = 300 ms, matrix 256  ! 256, pixel dimensions 0.98  ! 0.98 
mm, slice thickness 1.49 mm; (2) FLAIR – axial, TR = 9,000 ms, 
TE = 105 ms, TI = 2,200 ms, matrix 256  ! 256  ! 17, pixel dimen-
sions 0.98  ! 0.98 mm, slice thickness 5.0 mm.
 Hc Volumetry and Visual Ratings 
 To examine the occurrence and extent of Hc atrophy, both vi-
sual and volumetric assessments were performed. Both raters 
(L.v.d.P. and A. Hensel) were blinded to diagnosis, age and iden-
tity of the patients as well as each other’s rating results.
 All visual assessments were performed by L.v.d.P. Hc atrophy 
was visually assessed by the MTA rating scale  [5] . MTA was rated 
on coronal MPRAGE images separately for each hemisphere. For 
the purpose of this study, the maximum score for either hemi-
sphere was recorded. In addition, age-related white matter chang-
es (ARWMC) were rated on the axial FLAIR images using the 
ARWMC scale  [18] . Ten scans were rated twice (by L.v.d.P.) to as-
sess intrarater reliability. The   values were 0.7 for the MTA rating 
and 0.8 for the ARWMC rating. 
 Hc volumetry was performed by A. Hensel on the MPRAGE 
images using the BRIAN software package. Volumetric datasets 
were transferred to a UNIX system and processed as previously 
described  [19] . Six cross-sections of the hippocampus were seg-
mented manually in the coronal plane on both hemispheres. The 
left and right Hc volumes were summed to yield the total Hc vol-
ume.
 All patients and controls provided written informed consent 
for their clinical data to be used for research. The study received 
ethical approval by the local ethics committee at the VU Univer-
sity Amsterdam.
 Statistical Analyses 
 All statistical computations were performed using SPSS for 
Windows (version 12.0.0). The significance level was set to be 0.05 
for all analyses. Group differences in Hc volumes as well as MTA 
and ARWMC scores were assessed by the Kruskal-Wallis H test, 
followed by groupwise comparison by Mann-Whitney U tests.
 Results 
 The sample characteristics are summarized in  table 1 . 
Controls and disease groups were accurately matched re-
garding age and gender. Concerning severity of cognitive 
impairment and duration of symptoms, the disease 
groups compared well. In accordance with the diagnoses, 
white matter changes were significantly more pro-
nounced in SVaD patients than in AD patients and con-
trols. 
 Hc volumes were significantly reduced in both SVaD 
and AD – by 11.6 and 16.6%, respectively – as compared 
with controls (Kruskal-Wallis test; p = 0.002). Hc vol-
umes in SVaD were intermediate and differed signifi-
cantly from AD (p = 0.001) and controls (p = 0.015) ( fig. 1 ). 
The MTA ratings confirmed this pattern ( table 2 ). The 
MTA scores differed significantly between the three 
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groups (Kruskal-Wallis test; p = 0.001), and MTA rating 
scores in SVaD were intermediate between controls and 
AD patients, with significant differences between SVaD 
and controls (p = 0.002) as well as between SVaD and AD 
(p = 0.001). Nine SVaD as well as 9 AD patients, but only 
2 controls, had MTA scores of 2 or greater. Moderate 
(score 3) and severe atrophy (score 4) tended to be more 
common in patients with AD compared with SVaD (7
vs. 4).
 Discussion 
 To our knowledge, this is the first study to quantify Hc 
atrophy in stringently defined SVaD in comparison to 
AD and healthy controls. In contrast to other studies us-
ing heterogeneous definitions of vascular dementia, the 
disease groups were accurately matched for level of glob-
al cognitive impairment, age and gender. 
 Subjects with SVaD had significant Hc atrophy, evi-
dent by both Hc volumetry and visual rating of MTA 
scores as compared with controls. While MTA and Hc 
volume reductions in SVaD occurred with a comparable 
frequency to AD, Hc atrophy was significantly less severe 
than in AD. These findings are comparable with a num-
ber of previous studies showing that Hc atrophy com-
monly occurs in vascular dementia  [7, 9–13] and might 
be milder than in AD  [7, 9, 11] . However, none of these 
studies strictly focused on SVaD. 
 The mechanisms of Hc atrophy in SVaD remain un-
clear and could be heterogeneous. One possible explana-
tion for our findings is that cooccurrent Alzheimer pa-
thology, particularly neurofibrillary tangles (NFT), may 
have contributed to the Hc atrophy seen in SVaD. Close 
Table 1.  Description of the sample
SVaD AD Control
Number1 11 (4) 11 (4) 11 (4)
Age, years 6788 6988 6888
MMSE score
Mean 8 SD 2283 2283 2882
Range 16–27 17–26 24–30
CDR score, n
0.5 3 4 0
1 8 5 0
2 0 2 0
Symptom duration, years 382 483 0
Hc volume left + right, cm3 3.2080.32 3.0280.34 3.6280.37
ARWMC rating
Median 17 1 4
Range 7–21 0–6 5–20
V alues are means 8 SD unless specified otherwise. In 3 cases 
(2 SVaD, 1 control), the MMSE score was missing.
1 Values in parentheses denote numbers of females.
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 Fig. 1. Boxplot of total Hc volume estimate in patients with SVaD 
and AD and in healthy controls (HC; n = 33). Boxes: interquartile 
range. Lines in boxes: medians. Outliers are displayed individu-
ally. 
Table 2.  MTA ratings
N umber of subjects 
cont rol SVaD AD
MTA score
0 ( no atrophy) 3 0 0
1 6 2 2
2 2 5 2
3 0 3 6
4 (most severe atrophy) 0 1 1
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correlations have been shown between Hc neuronal loss, 
NFT and Hc atrophy in cases with AD  [20] , and even 
across different dementia disorders  [10] .
 However, Hc atrophy in SVaD has been shown to oc-
cur in the absence of AD pathology. In postmortem stud-
ies, up to 50% of cases with SVaD were found to have 
Braak stages of 0/I, i.e. negligible NFT pathology  [20–22] . 
Yet, there was significant Hc pyramidal cell loss in some 
of these cases  [21] . The most important findings in sup-
port of ‘pure’ vascular mechanisms of Hc atrophy derive 
from cases with CADASIL (cerebral autosomal dominant 
arteriopathy with subcortical infarcts and leukoencepha-
lopathy). These patients often have pronounced Hc atro-
phy correlating with their global cognitive state, but be-
cause they are aged  ! 60 years, comorbid Alzheimer pa-
thology is unlikely  [23] .
 In a large histopathological case series of ischemic vas-
cular dementia, some manner of Hc injury was common-
ly found and the substrates were noted to be extremely 
variable, ranging from regions with cystic encephaloma-
lacia to well-defined regions with segmental Hc scarring, 
resembling Hc sclerosis  [22] .
 In our sample, patients with SVaD had significantly 
less Hc atrophy despite the same degree of global cogni-
tive disturbances as AD patients (MMSE score 22), but 
the quantitative difference was small (5%). Larger studies 
on vascular dementia add plausibility to this finding by 
showing that Hc atrophy is the major correlate of global 
cognition in vascular dementia, whereas white matter le-
sions contribute more specifically to executive dysfunc-
tion  [24] . Beyond easily detectable radiological phenom-
ena of white matter lesions and Hc atrophy, the choliner-
gic denervation caused by ischemic damage to fiber tracts 
appears to be of specific pathophysiological relevance
in SVaD  [25] . Differing pathophysiological mechanisms 
(neurodegenerative vs. microvascular) could result in 
shape and texture differences, possibly leading to small 
but significant differences in Hc volume between AD and 
SVaD. This needs to be addressed in future imaging 
 studies.
 Some limitations of our study have to be mentioned. 
The sample size was small, but the design was optimized 
to create homogeneous groups and to avoid the use of sta-
tistical corrections. It remains unclear whether the volu-
metric estimations from our study can be generalized. 
The Hc volume loss in the AD group was rather small 
compared with other studies, some of which used the 
same protocol  [19, 26] . This could be due to the relatively 
young age, mild disease severity or chance. A smaller 
than expected Hc volume loss in AD decreases the power 
to detect a true group difference, and hence also the like-
lihood of a type I error.
 In conclusion, patient groups with AD and SVaD as 
identified by current research criteria appear to overlap 
considerably with regard to the feature of Hc atrophy. 
While contamination with AD is a likely cause, other 
mechanisms of Hc atrophy in SVaD also deserve consid-
eration. In future trials of SVaD, the degree of Hc atrophy 
should be taken into account in addition to the defining 
features.
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